中際旭創(300308.SZ):是現階段海外重點客户已認證的800G光模塊少數供應商之一,已取得客户的批量訂單且出貨量預計逐季增長
格隆匯5月6日丨中際旭創(300308.SZ)於2023年5月5日15:00-17:00召開2022年度網上業績説明會,問答環節中,就“為什麼競品公司稱目前還看不到800g需求放量,而貴司800g逐月訂單提升?”,公司表示,海外重點客户已在去年四季度開始逐步上量部署800G,公司是現階段海外重點客户已認證的800G光模塊少數供應商之一,已取得客户的批量訂單且出貨量預計逐季增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.